Category Archives: Dermal Papilla Cells

Effective Cell Therapy for Hair Regeneration

Update: Epibiotech CEO Sung (who is the author of the new paper covered in this post) is answering our questions in the comments this week. Please note that English is not his first language.


Earlier this month, Epibiotech CEO Jong-Hyuk Sung published a detailed new paper titled “Effective and economical cell therapy for hair regeneration.” It was widely covered in South Korean media (h/t “Theo”, who also sent me this update on Mr. Sung’s presentation covering the paper). They call him Seong Jong-Hyeok in that article.

My interest piqued when I read such a thorough scientific paper from a CEO (almost unheard of in this industry). I showed it to a well known hair transplant doctor, and he found it to be a great summary. I also e-mailed one of Epibiotech’s media representatives with some questions, but no response so far.

Adipose, Dermal Papilla and Dermal Sheath Cells

Note that Dr. Sung has publiched numerous papers on adipose-derived stem cells (ADSC) and hair regeneration (and wound healing) for 15 years. This CEO seems to be a scientist first and foremost, rather than a business person.

This latest paper covers the three main types of cell based hair regeneration treatment strategies that are currently being developed:

  1. Adipose-derived stem cells (ADSC or ASC).
  2. Dermal papilla cells (DPC).
  3. Dermal papilla epithelial cup cells, better kown as dermal sheath cup cells (DPSC or DSC).

The paper also mentions the manufacturing of hair organoids using induced pluripotent stem cells. Including a shout out to Dr. Takashi Tsuji.

  • Note that Shiseido (including its use of Replicel’s technology) is working on a hair regeneration treatment involving culturing of dermal sheath cup cells. More details here.
  • Also note that in the past, Aderans and Intercytex both saw some succes in hair growth via dermal papilla cell culturing and injection into balding scalps. HairClone is currently trying something similar.

Dr. Sung’s company Epibiotech is ultimately driven by “Off-the-shelf” allogeneic DPC therapy. It aims to begin Phase 1 clinical trials for its EPI-001 dermal papilla cell hair multiplication treatment in 2023. We are all hopeful that things will move faster in Asia in comparison to the US or Western Europe. The company can already mass-produce dermal papilla cells with hair growth ability using spheroid culture, hypoxic conditions, and growth factors.

Cell Therapy Hair Growth
Cell therapy for hair growth. Adipose, dermal papilla and dermal sheath cup cells. Source: Biomedicine & Pharmacotherapy, January 2023.

Adipose Derived Stem Cells

Given the author’s background, the paper is especially detailed when it comes to ADSC (ASC). Dr. Sung highlights the pros and cons.

    • Adipose-derived stem cells are easy to access and isolate in large quantities. This is not true when it comes to dermal papilla cells and dermal sheath cup cells.
    • While ASCs promote hair growth through the paracrine effect, they have a poor potential in hair neogenesis. Dr. Sung suggests further development in methods to enhance the trichogenecity of ASCs.

Other New Studies on Hair Regeneration

As if this was not enough, two new papers on hair regenearation came out in the past month.

  • A lierature review from Japan coveres numerous cell therapies for hair regrowth. This includes mesenchymal stem cell (MSC) implantation. Adult sources of MSC include: adipose tissue (including SVF); bone marrow; DPC; DSC; placenta and umbilical cord. The paper also analyzes non-cell therapies, including exosomes, extracellular matrix, platelet-rich plasma, and the MSC secretome. The last mentioned “comprises bioactive materials, such as growth factors, cytokines and nucleic acids that play an important role in regulating the hair follicle cycle and regeneration”.
  • A new study from China on microenvironmental reprogramming of human dermal papilla cells for hair follicle tissue engineering.
  • And finally, a recent video on regenerative medicine for hair loss starring Dr. Jerry Cooley (interviewed by Dr. Robert Haber).

SCUBE3 Signaling Molecule for Hair Growth

I have covered Dr. Maksim Plikus a few times on this blog in the past. I have also discussed Hedgehog signaling and hair growth in detail. Yesterday, a University of California team (led by Dr. Plikus) discovered a critical signaling molecule SCUBE3 that stimulates hair growth.

Update: July 29, 2022

Yet another update just came out (h/t “YoYo”). I like the phrase “digitize the hair“.

Update: July 18, 2022

New video titled: “UC Irvine scientists discover a possible cure for baldness.” Starring Dr. Maksim Plikus (h/t “YoYo”). And yet another one.

Update: July 7, 2022

Dr. William Rassman provided an update on Reddit on July 7:

 SCUBE3 Signaling Molecule Trials via Amplifica
Amplifica is a biotechnology company that was co-founded by Maksim Plikus and Dr. William Rassman. They plan to begin SCUBE3 clinical trials by the end of 2022.

SCUBE3 represents one part of the interconnected hair growth loop that also includes the hedgehog pathway, dermal papilla cells, TGF-β and Wnt5a. This interaction is shown in the below diagram from this latest research.

SCUBE3 Hair Growth
SCUBE3 signaling molecule stimulates hair growth. Source: Development Cell.

July 1, 2022

SCUBE3 Signaling Molecule Stimulates Hair Growth

University of California, Irvine (UCI) led researchers have discovered that a signaling molecule (which they call SCUBE3) potently stimulates hair growth. Most importantly, it may offer a therapeutic treatment for androgenetic alopecia, which accounts for 90-95 percent of hair loss cases in both men and women.

The actual study was published yesterday in Development Cell. The study team included health professionals and academics from UCI, San Diego, China, Japan, Korea and Taiwan.

“UCI has filed a provisional patent application on the use of SCUBE3 and its related molecular compounds for hair growth stimulation.”

This study discovered the precise mechanism by which the dermal papilla cells (fibroblasts at the bottom of each hair follicle) promote new growth. According to Dr. Plikus:

“We revealed that the SCUBE3 signaling molecule, which dermal papilla cells produce naturally, is the messenger used to ‘tell’ the neighboring hair stem cells to start dividing, which heralds the onset of new hair growth.”

In people with androgenetic alopecia, dermal papilla cells start to malfunction. One of the reasons behind this is a major reduction in the normally abundant signaling and activating molecules. It seems like SCUBE3 protein microinjections are sufficient to induce new hair growth.

However, note that mice were involved in this initial work. The research team microinjected SCUBE3 into mouse skin in which human scalp follicles had been transplanted. This induced new growth in both the dormant human hair follicles and surrounding mouse follicles due to “hyperactivated” dermal papilla cells.

Per co-first author and UCI postdoctoral researcher Christian Guerrero-Juarez, these experiments provide proof that SCUBE3 or derived molecules can be a promising therapeutic for hair loss.

According to Dr. Plikus, there is a strong need for new, effective hair loss medications. Naturally occurring compounds that are used by dermal papilla cells for hair growth “present ideal next-generation” candidates for pattern baldness treatment.

More detailed research on this subject will be conducted in the Plikus Lab and at Amplifica Holdings Group. The latter is a biotechnology company that was co-founded by Plikus and includes Dr. William Rassman on its team. For more on Amplifica, see the section in this article titled: “Amplifica Treats Baldness with Mole Molecules.”